Cargando…
Updates of incretin‐related drugs for the treatment of type 2 diabetes
Mechanisms of dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide‐1 receptor agonists and glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor dual‐agonist in glycemic control and/or weight loss.[Image: see text]
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889679/ https://www.ncbi.nlm.nih.gov/pubmed/36373430 http://dx.doi.org/10.1111/jdi.13945 |